Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies.
CEO Thomas Joyce said that the company's pending $13.8 billion buy of Pall has received US regulatory approval and an EU decision is expected next month.
The company replaced an existing $2.5 billion facility with an amended and restated $4 billion facility and entered into a new $7 billion facility.
Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.
The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.
Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.
The company lowered its full-year 2015 adjusted EPS estimate on anticipated tougher currency effects.
Core revenues at Beckman Coulter and AB Sciex grew in the mid-single digits during the fourth quarter, CEO Thomas Joyce noted.
Officials from Thermo Fisher Scientific, Affymetrix, Danaher, Hologic, Genmark, and Accelerate Diagnostics provided strategic updates at the conference.
Mass spec instrumentation showed solid growth in Q3, with particular strength in academic and government markets.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.